Pfizer Inc. $PFE Shares Sold by Sarasin & Partners LLP

Sarasin & Partners LLP decreased its holdings in Pfizer Inc. (NYSE:PFE) by 37.7% in the 2nd quarter, HoldingsChannel reports. The firm owned 845,257 shares of the biopharmaceutical company’s stock after selling 510,530 shares during the quarter. Sarasin & Partners LLP’s holdings in Pfizer were worth $20,354,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Evolution Wealth Management Inc. grew its position in Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 566 shares in the last quarter. Godfrey Financial Associates Inc. acquired a new stake in shares of Pfizer in the 4th quarter worth approximately $26,000. HFM Investment Advisors LLC lifted its stake in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 427 shares during the period. Global Trust Asset Management LLC boosted its holdings in shares of Pfizer by 126.7% in the first quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 650 shares in the last quarter. Finally, Abound Financial LLC acquired a new position in shares of Pfizer during the fourth quarter valued at approximately $31,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q2 earnings beat and guidance increase: Pfizer reported adjusted earnings of $0.77 per share versus the $0.68 consensus estimate, while revenue of $15.03 billion exceeded expectations of $14.40 billion. Management raised the low end of its 2026 revenue outlook, supported by Eliquis and other non-COVID products. Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost Cuts
• Positive Sentiment: Cost savings and pipeline support: Pfizer expanded its cost-reduction target, providing a potential lift to future margins and cash flow. Analysts also highlighted continued growth in newer products and a broader R&D pipeline as offsets to declining COVID revenue. PFE Q2 Deep Dive: New Products Offset COVID Decline, R&D Pipeline Expands
• Positive Sentiment: Clinical catalysts: Pfizer reported positive Phase 3 data for LITFULO in vitiligo and announced progress in a pediatric COVID booster study. It also completed a Phase 1 study of PF-07328948, adding incremental support to its longer-term pipeline narrative. Pfizer Reports Positive Phase 3 LITFULO Data in Vitiligo
• Neutral Sentiment: Analyst view remains mixed: Some coverage describes Pfizer as attractive for income investors because of its high dividend yield and potential undervaluation, while RBC Capital maintained a Hold rating. Investors remain focused on execution and the sustainability of the recovery. RBC Capital Remains a Hold on Pfizer
• Negative Sentiment: COVID and pipeline risks persist: COVID pill revenue reportedly fell 95%, and setbacks surrounding Pfizer’s obesity program, along with upcoming patent expirations, continue to raise concerns about long-term growth. These risks explain why the market’s response remains measured despite the earnings beat. Pfizer Covid Pill Revenue Plunges 95%

Analysts Set New Price Targets

Several brokerages recently commented on PFE. Bank of America dropped their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Morgan Stanley lifted their price target on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Wolfe Research reissued an “underperform” rating and issued a $26.00 price objective on shares of Pfizer in a research note on Thursday, May 14th. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Pfizer in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.50.

Pfizer Price Performance

Shares of NYSE:PFE opened at $26.18 on Friday. The company has a market capitalization of $149.24 billion, a PE ratio of 34.45 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.94 and a current ratio of 1.27. The stock has a fifty day moving average of $25.01 and a 200-day moving average of $26.16. Pfizer Inc. has a one year low of $23.58 and a one year high of $28.75.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. Pfizer’s dividend payout ratio (DPR) is currently 226.32%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.